TY - JOUR
T1 - Daunomycin treatment prevents clinical expression of experimental autoimmune myasthenia gravis
AU - Christadoss, Premkumar
AU - Henderson, Regina
AU - Keve, Steve
N1 - Funding Information:
We thank Dr. Roy Korson (pathologist) for his expert histological evaluation of various samples, and Drs. Thomas T&ton and Sheldon Cooper for reviewing the manuscript and their opinion. This work was supported by a grant from the Muscular Dystrophy Association. We also thank Barbara Cady for typing this manuscript.
Copyright:
Copyright 2014 Elsevier B.V., All rights reserved.
PY - 1991/5
Y1 - 1991/5
N2 - Myasthenia gravis (MG) is an autoimmune neuromuscular disease, characterized by muscle weakness and electrophysiological abnormality. No treatment which would reliably induce permanent clinical remission of MG is yet available. The therapeutic efficacy and toxic effect of daunomvcin (Dm), an antibiotic of the rhodomycin group, was evaluated in murine experimental autoimmune MG. Low dosage Dm treatment effectively prevented the development of muscle weakness and its associated electrophysiological abnormality, without inducing detectable toxicity and global immunosuppression.
AB - Myasthenia gravis (MG) is an autoimmune neuromuscular disease, characterized by muscle weakness and electrophysiological abnormality. No treatment which would reliably induce permanent clinical remission of MG is yet available. The therapeutic efficacy and toxic effect of daunomvcin (Dm), an antibiotic of the rhodomycin group, was evaluated in murine experimental autoimmune MG. Low dosage Dm treatment effectively prevented the development of muscle weakness and its associated electrophysiological abnormality, without inducing detectable toxicity and global immunosuppression.
UR - http://www.scopus.com/inward/record.url?scp=0025859317&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025859317&partnerID=8YFLogxK
U2 - 10.1016/0090-1229(91)90022-3
DO - 10.1016/0090-1229(91)90022-3
M3 - Article
C2 - 2009643
AN - SCOPUS:0025859317
SN - 0090-1229
VL - 59
SP - 246
EP - 255
JO - Clinical Immunology and Immunopathology
JF - Clinical Immunology and Immunopathology
IS - 2
ER -